Where Will CASI Pharmaceuticals Inc (CASI) Stock Go Next After It Is Higher By 20.42% in a Week?

CASI Pharmaceuticals Inc (CASI) stock is higher by 20.42% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

CASI Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CASI!

See Full CASI Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CASI Stock Today?

CASI Pharmaceuticals Inc (CASI) stock is trading at $4.01 as of 10:41 AM on Wednesday, Nov 1, a rise of $0.09, or 2.22% from the previous closing price of $3.92. The stock has traded between $3.95 and $4.26 so far today. Volume today is below average. So far 23,090 shares have traded compared to average volume of 35,128 shares. To see InvestorsObserver's Sentiment Score for CASI Pharmaceuticals Inc click here.

More About CASI Pharmaceuticals Inc

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world. Click Here to get the full Stock Report for CASI Pharmaceuticals Inc stock.